(Q44849439)

English

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert L. Murphy

22

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Christine Katlama

21

object named as

C Katlama

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

23

object named as

A Horban

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

F van Leth

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

P Phanuphak

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

K Ruxrungtham

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

E Baraldi

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

S Miller

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

B Gazzard

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

P Cahn

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

U G Lalloo

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

I P van der Westhuizen

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

D R Malan

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

M A Johnson

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

B R Santos

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

F Mulcahy

13

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

R Wood

14

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

G C Levi

15

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

G Reboredo

16

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

K Squires

17

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

I Cassetti

18

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

D Petit

19

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

F Raffi

20

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

J P Dam

24

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

E Hassink

25

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

R van Leeuwen

26

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

P Robinson

27

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

F W Wit

28

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

J M A Lange

29

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2NN Study team

30

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

363

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

9417

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1253-1263

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe adverse cutaneous reactions to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced liver injury: mechanisms and test systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915997-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(04)15997-7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44849439&oldid=2053846589"